Inbrain Neuroelectronics, S.L.

INBRAIN Neuroelectronics develops a graphene-based brain-computer interface platform. Its graphene interfaces read neural signals, and AI is used to turn those signals into real-time, personalized autonomous therapy.

The website describes patients and partners in pharma, technology and clinical research as the audience, and names collaborations with Merck, Mayo Clinic and Microsoft. The website does not describe the revenue model.

The company states it has been building since 2020 and has 115+ people across neuroscience, semiconductors, AI and clinical development. It has an FDA Breakthrough Device Designation for Parkinson's disease therapy (2023), was accepted into the FDA TAP program (2024), and reported a first human procedure with its graphene BCI in September 2024. Open roles are listed in Barcelona across engineering, quality, manufacturing, machine learning, finance and clinical operations.

Product: Graphene-based brain-computer interface platform that reads neural signals and modulates neural function with AI-driven therapy.